Pathology: mBC - TNBC - L2 - all population; mBC-Triple negative (TNBC) - 2nd Line (L2);
| mBC - TNBC - L2 - all population | mBC-Triple negative (TNBC) - 2nd Line (L2) | ||
| OlympiAD, 2017 | EMBRACA, 2018 | ||
| talazoparib | 1 | T1 | |
| olaparib | 1 | T1 | |
| Standard of Care (SoC) | 0 | T0 | T0 |